{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T16:20:18Z","timestamp":1790698818379,"version":"4.1.0"},"update-to":[{"DOI":"10.1371\/journal.pntd.0010953","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T00:00:00Z","timestamp":1671667200000}}],"reference-count":30,"publisher":"Public Library of Science (PLoS)","issue":"12","license":[{"start":{"date-parts":[[2022,12,12]],"date-time":"2022-12-12T00:00:00Z","timestamp":1670803200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["OPP1184344"],"award-info":[{"award-number":["OPP1184344"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["OPP1184344"],"award-info":[{"award-number":["OPP1184344"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["OPP1184344"],"award-info":[{"award-number":["OPP1184344"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["OPP1184344"],"award-info":[{"award-number":["OPP1184344"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["OPP1184344"],"award-info":[{"award-number":["OPP1184344"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["OPP1184344"],"award-info":[{"award-number":["OPP1184344"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["OPP1184344"],"award-info":[{"award-number":["OPP1184344"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["OPP1184344"],"award-info":[{"award-number":["OPP1184344"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["OPP1184344"],"award-info":[{"award-number":["OPP1184344"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["OPPGH5342"],"award-info":[{"award-number":["OPPGH5342"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["OPPGH5342"],"award-info":[{"award-number":["OPPGH5342"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["OPPGH5342"],"award-info":[{"award-number":["OPPGH5342"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["OPPGH5342"],"award-info":[{"award-number":["OPPGH5342"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["OPPGH5342"],"award-info":[{"award-number":["OPPGH5342"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["OPPGH5342"],"award-info":[{"award-number":["OPPGH5342"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["OPPGH5342"],"award-info":[{"award-number":["OPPGH5342"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["OPPGH5342"],"award-info":[{"award-number":["OPPGH5342"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003246","name":"Nederlandse Organisatie voor Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["016.Veni.178.023"],"award-info":[{"award-number":["016.Veni.178.023"]}],"id":[{"id":"10.13039\/501100003246","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosntds.org"],"crossmark-restriction":false},"short-container-title":["PLoS Negl Trop Dis"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Mass drug administration (MDA) is the main strategy towards lymphatic filariasis (LF) elimination. Progress is monitored by assessing microfilaraemia (Mf) or circulating filarial antigenaemia (CFA) prevalence, the latter being more practical for field surveys. The current criterion for stopping MDA requires &lt;2% CFA prevalence in 6- to 7-year olds, but this criterion is not evidence-based. We used mathematical modelling to investigate the validity of different thresholds regarding testing method and age group for African MDA programmes using ivermectin plus albendazole.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methodolgy\/Principal findings<\/jats:title>\n                    <jats:p>We verified that our model captures observed patterns in Mf and CFA prevalence during annual MDA, assuming that CFA tests are positive if at least one adult worm is present. We then assessed how well elimination can be predicted from CFA prevalence in 6-7-year-old children or from Mf or CFA prevalence in the 5+ or 15+ population, and determined safe (&gt;95% positive predictive value) thresholds for stopping MDA. The model captured trends in Mf and CFA prevalences reasonably well. Elimination cannot be predicted with sufficient certainty from CFA prevalence in 6-7-year olds. Resurgence may still occur if all children are antigen-negative, irrespective of the number tested. Mf-based criteria also show unfavourable results (PPV &lt;95% or unpractically low threshold). CFA prevalences in the 5+ or 15+ population are the best predictors, and post-MDA threshold values for stopping MDA can be as high as 10% for 15+. These thresholds are robust for various alternative assumptions regarding baseline endemicity, biological parameters and sampling strategies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Conclusions\/Significance<\/jats:title>\n                    <jats:p>For African areas with moderate to high pre-treatment Mf prevalence that have had 6 or more rounds of annual ivermectin\/albendazole MDA with adequate coverage, we recommend to adopt a CFA threshold prevalence of 10% in adults (15+) for stopping MDA. This could be combined with Mf testing of CFA positives to ensure absence of a significant Mf reservoir for transmission.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pntd.0010953","type":"journal-article","created":{"date-parts":[[2022,12,12]],"date-time":"2022-12-12T13:37:57Z","timestamp":1670852277000},"page":"e0010953","update-policy":"https:\/\/doi.org\/10.1371\/journal.pntd.corrections_policy","source":"Crossref","is-referenced-by-count":14,"title":["Comparing antigenaemia- and microfilaraemia as criteria for stopping decisions in lymphatic filariasis elimination programmes in Africa"],"prefix":"10.1371","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9509-1328","authenticated-orcid":true,"given":"Wilma A.","family":"Stolk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc E.","family":"Coffeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatorma K.","family":"Bolay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Obiora A.","family":"Eneanya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter U.","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T. D\u00e9irdre","family":"Hollingsworth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin G.","family":"Koudou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aboulaye","family":"M\u00e9it\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edwin","family":"Michael","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaquin M.","family":"Prada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rocio M.","family":"Caja Rivera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swarnali","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panayiota","family":"Touloupou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary J.","family":"Weil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sake J.","family":"de Vlas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2022,12,12]]},"reference":[{"key":"pntd.0010953.ref001","first-page":"509","volume":"95","year":"2019","journal-title":"2020) Global programme to eliminate lymphatic filariasis: progress report"},{"key":"pntd.0010953.ref002","volume-title":"Guideline: alternative mass drug administration regimens to eliminate lymphatic filariasis.:","author":"World Health Organization","year":"2017"},{"key":"pntd.0010953.ref003","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1046\/j.1365-3156.2000.00620.x","article-title":"The global programme to eliminate lymphatic filariasis","volume":"5","author":"EA Ottesen","year":"2000","journal-title":"Trop Med Int Health"},{"key":"pntd.0010953.ref004","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1475-2883-6-2","article-title":"Morbidity management in the Global Programme to Eliminate Lymphatic Filariasis: A review of the scientific literature","volume":"6","author":"DG Addiss","year":"2007","journal-title":"Filaria J"},{"key":"pntd.0010953.ref005","first-page":"497","volume":"96","year":"2020","journal-title":"2021) Global programme to eliminate lymphatic filariasis: progress report"},{"key":"pntd.0010953.ref006","volume-title":"Monitoring and epidemiological assessment of mass drug administration in the global programme to eliminate lymphatic filariasis: a manual for national elimination programmes:","author":"World Health Organization","year":"2011"},{"key":"pntd.0010953.ref007","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/bs.apar.2020.04.007","article-title":"Contributions to the lymphatic filariasis elimination programme and post-elimination surveillance in China by NIPD-CTDR","volume":"110","author":"D-J Sun","year":"2020","journal-title":"Adv Parasitol"},{"key":"pntd.0010953.ref008","doi-asserted-by":"crossref","first-page":"3","DOI":"10.4269\/ajtmh.13-0202","article-title":"Rapid diagnostics for the endgame in lymphatic filariasis elimination","volume":"89","author":"MP Rebollo","year":"2013","journal-title":"Am J Trop Med Hyg"},{"key":"pntd.0010953.ref009","article-title":"Diagnostic tools for filariasis elimination programs","author":"GJ Weil","year":"2007","journal-title":"Trends Parasitol"},{"key":"pntd.0010953.ref010","doi-asserted-by":"crossref","first-page":"e2584","DOI":"10.1371\/journal.pntd.0002584","article-title":"Transmission assessment surveys (TAS) to define endpoints for lymphatic filariasis mass drug administration: a multicenter evaluation","volume":"7","author":"BK Chu","year":"2013","journal-title":"PLoS Negl Trop Dis"},{"key":"pntd.0010953.ref011","doi-asserted-by":"crossref","first-page":"e0007365","DOI":"10.1371\/journal.pntd.0007365","article-title":"Systematic sampling of adults as a sensitive means of detecting persistence of lymphatic filariasis following mass drug administration in Sri Lanka","volume":"13","author":"RU Rao","year":"2019","journal-title":"PLoS Negl Trop Dis"},{"key":"pntd.0010953.ref012","doi-asserted-by":"crossref","first-page":"11","DOI":"10.4269\/ajtmh.13-0089","article-title":"Laboratory and field evaluation of a new rapid test for detecting Wuchereria bancrofti antigen in human blood","volume":"89","author":"GJ Weil","year":"2013","journal-title":"Am J Trop Med Hyg"},{"key":"pntd.0010953.ref013","doi-asserted-by":"crossref","first-page":"e0005703","DOI":"10.1371\/journal.pntd.0005703","article-title":"A multi-center field study of two point-of-care tests for circulating Wuchereria bancrofti antigenemia in Africa","volume":"11","author":"CB Chesnais","year":"2017","journal-title":"PLoS Negl Trop Dis"},{"key":"pntd.0010953.ref014","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1093\/aje\/kwz109","article-title":"Predictive value of Ov16 antibody prevalence in different subpopulations for elimination of African onchocerciasis","volume":"188","author":"LE Coffeng","year":"2019","journal-title":"Am J Epidemiol"},{"key":"pntd.0010953.ref015","doi-asserted-by":"crossref","first-page":"S503","DOI":"10.1093\/infdis\/jiz647","article-title":"Elimination or Resurgence: Modelling Lymphatic Filariasis After Reaching the 1% Microfilaremia Prevalence Threshold","volume":"221","author":"JM Prada","year":"2020","journal-title":"J Infect Dis"},{"key":"pntd.0010953.ref016","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1017\/S0031182008000437","article-title":"LYMFASIM, a simulation model for predicting the impact of lymphatic filariasis control: quantification for African villages","volume":"135","author":"WA Stolk","year":"2008","journal-title":"Parasitology"},{"key":"pntd.0010953.ref017","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1017\/S0031182004004822","article-title":"The dynamics of Wuchereria bancrofti infection: a model-based analysis of longitudinal data from Pondicherry, India","volume":"128","author":"S Subramanian","year":"2004","journal-title":"Parasitology"},{"key":"pntd.0010953.ref018","article-title":"Impact of annual versus semiannual mass drug administration with ivermectin and albendazole on helminth infections in southeastern Liberia","volume":"106","author":"OA Eneanya","year":"2021","journal-title":"Am J Trop Med Hyg"},{"key":"pntd.0010953.ref019","doi-asserted-by":"crossref","first-page":"e0008033","DOI":"10.1371\/journal.pntd.0008033","article-title":"Modelling for policy: the five principles of the Neglected Tropical Diseases Modelling Consortium","volume":"14","author":"MR Behrend","year":"2020","journal-title":"PLoS Negl Trop Dis"},{"key":"pntd.0010953.ref020","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1111\/j.1365-3156.1997.tb00157.x","article-title":"Ivermectin for the chemotherapy of bancroftian filariasis: a meta-analysis of the effect of single treatment","volume":"2","author":"WC Cao","year":"1997","journal-title":"Trop Med Int Health"},{"key":"pntd.0010953.ref021","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1046\/j.1365-3156.1996.d01-79.x","article-title":"Ultrasonographic assessment of the adulticidal efficacy of repeat high-dose ivermectin in bancroftian filariasis","volume":"1","author":"G Dreyer","year":"1996","journal-title":"Trop Med Int Health"},{"key":"pntd.0010953.ref022","doi-asserted-by":"crossref","first-page":"e0008644","DOI":"10.1371\/journal.pntd.0008644","article-title":"Defining a prevalence level to describe the elimination of Lymphatic Filariasis (LF) transmission and designing monitoring & evaluating (M&E) programmes post the cessation of mass drug administration (MDA)","volume":"14","author":"BS Collyer","year":"2020","journal-title":"PLoS Negl Trop Dis"},{"key":"pntd.0010953.ref023","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1093\/trstmh\/trv096","article-title":"Understanding the relationship between prevalence of microfilariae and antigenaemia using a model of lymphatic filariasis infection","volume":"110","author":"MA Irvine","year":"2016","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"pntd.0010953.ref024","doi-asserted-by":"crossref","first-page":"e3281","DOI":"10.1371\/journal.pntd.0003281","article-title":"A comprehensive assessment of lymphatic filariasis inSri Lanka six years after cessation of mass drug administration","volume":"8","author":"RU Rao","year":"2014","journal-title":"PLoS Negl Trop Dis"},{"key":"pntd.0010953.ref025","doi-asserted-by":"crossref","first-page":"e0004722","DOI":"10.1371\/journal.pntd.0004722","article-title":"Programmatic Use of Molecular Xenomonitoring at the Level of Evaluation Units to Assess Persistence of Lymphatic Filariasis in Sri Lanka","volume":"10","author":"RU Rao","year":"2016","journal-title":"PLoS Negl Trop Dis"},{"key":"pntd.0010953.ref026","doi-asserted-by":"crossref","first-page":"735","DOI":"10.4269\/ajtmh.18-0169","article-title":"Comprehensive Assessment of a Hotspot with Persistent Bancroftian Filariasis in Coastal Sri Lanka","volume":"99","author":"RU Rao","year":"2018","journal-title":"Am J Trop Med Hyg"},{"key":"pntd.0010953.ref027","doi-asserted-by":"crossref","first-page":"e0005914","DOI":"10.1371\/journal.pntd.0005914","article-title":"Detecting and confirming residual hotspots of lymphatic filariasis transmission in American Samoa 8 years after stopping mass drug administration","volume":"11","author":"CL Lau","year":"2017","journal-title":"PLoS Negl Trop Dis"},{"key":"pntd.0010953.ref028","doi-asserted-by":"crossref","first-page":"e0006583","DOI":"10.1371\/journal.pntd.0006583","article-title":"Identifying residual transmission of lymphatic filariasis after mass drug administration: Comparing school-based versus community-based surveillance\u2014American Samoa, 2016","volume":"12","author":"M Sheel","year":"2018","journal-title":"PLoS Negl Trop Dis"},{"key":"pntd.0010953.ref029","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.ijpara.2010.12.009","article-title":"Control of onchocerciasis in Africa: threshold shifts, breakpoints and rules for elimination","volume":"41","author":"HP Duerr","year":"2011","journal-title":"Int J Parasitol"},{"key":"pntd.0010953.ref030","doi-asserted-by":"crossref","first-page":"e0006624","DOI":"10.1371\/journal.pntd.0006624","article-title":"The effect of assortative mixing on stability of low helminth transmission levels and on the impact of mass drug administration: Model explorations for onchocerciasis","volume":"12","author":"AS de Vos","year":"2018","journal-title":"PLoS Negl Trop Dis"}],"updated-by":[{"DOI":"10.1371\/journal.pntd.0010953","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T00:00:00Z","timestamp":1671667200000}}],"container-title":["PLOS Neglected Tropical Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pntd.0010953","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T13:58:35Z","timestamp":1671717515000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pntd.0010953"}},"subtitle":[],"editor":[{"given":"Marc P.","family":"Hubner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2022,12,12]]},"references-count":30,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2022,12,12]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pntd.0010953","relation":{},"ISSN":["1935-2735"],"issn-type":[{"value":"1935-2735","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,12]]}}}